Parabilis Medicines, Inc. (NASDAQ:PBLS) Given Consensus Recommendation of “Buy” by Analysts

Shares of Parabilis Medicines, Inc. (NASDAQ:PBLS) have earned a consensus recommendation of “Buy” from the six research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $41.6667.

Several equities research analysts recently issued reports on the stock. Evercore started coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They set an “outperform” rating on the stock. Leerink Partners initiated coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating and a $40.00 price objective for the company. Zacks Research upgraded Parabilis Medicines to a “hold” rating in a research note on Tuesday, July 7th. Guggenheim assumed coverage on Parabilis Medicines in a research report on Monday, July 6th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Lifesci Capital upgraded Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th.

Parabilis Medicines Stock Performance

Shares of PBLS stock opened at $33.98 on Friday. Parabilis Medicines has a twelve month low of $24.51 and a twelve month high of $34.47.

Insider Buying and Selling

In other Parabilis Medicines news, major shareholder Guy Levy bought 500,000 shares of the business’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $20.00 per share, with a total value of $10,000,000.00. Following the transaction, the insider directly owned 1,027,000 shares in the company, valued at approximately $20,540,000. This trade represents a 94.88% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Alan Sebulsky bought 9,065 shares of Parabilis Medicines stock in a transaction dated Monday, June 15th. The shares were acquired at an average price of $26.49 per share, with a total value of $240,131.85. Following the completion of the purchase, the director owned 30,000 shares in the company, valued at approximately $794,700. The trade was a 43.30% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 530,000 shares of company stock valued at $10,723,528.

Parabilis Medicines, Inc is a healthcare company in the Biotechnology industry.